A case of Lassa fever: clinical and virological findings.

Emond, R. T. D.; Bannister, Barbara; Lloyd, Graham; Southee, T.; Bowen, E. T. W.

doi:10.1136/bmj.285.6347.1001

Cited by 47 publications

(17 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody titres of both one-dose and two-dose sera were 1/2048, as estimated by indirect immunofluorescence on acetone-fixed Lassa-infected Vero cells. Human serum was obtained from a Lassa fever patient 68 days after the onset of symptoms (Emond et at., 1982). It had an immunofluorescence titre of 1/16000.…”

Section: Methodsmentioning

confidence: 99%

Structural and Cell-associated Proteins of Lassa Virus

Clegg

Lloyd

1983

Journal of General Virology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Structural and Cell-associated Proteins of Lassa Virus

Clegg

Lloyd

1983

Journal of General Virology

View full text Add to dashboard Cite

“…3 and 4). Taken together, these data, in regard to NHP convalescence and virus detection, may not be novel, given that infectious LASV has been observed months after convalescence in the urine of humans who have recovered from the illness 13 . It is possible that the timing of the 8.9F/12.1F/37.2D combination treatment of the +3 cohort led to a cell-associated state for the virus that did not lead to detectable release of virus.…”

mentioning

confidence: 93%

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Mire

Cross

Geisbert

et al. 2017

Nat Med

112

134

View full text Add to dashboard Cite

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.

show abstract

“…It is estimated that between 15-20% of all hospitalized Lassa fever patients are likely to die from the illness if appropriate medical intervention is not instituted early [3,10] On the other hand, epidemiological and immunological studies have shown that immunity developing in those who survived Lassa virus infection is long lasting [20,21].…”

Section: Epidemiological Trend Of Lassa Fevermentioning

confidence: 99%

“…Lassa virus is characterized by high genetic variability hence there was initial difficulty regarding the design of primers for Polymerase Chain Reaction (PCR) in molecular studies of the virus. Consequently, some Lassa virus strains were believed to escape, detection by PCR during the early studies [15,21]. Other members of the Old World African Arenaviruses that share similar properties and closely related to Lassa virus include Ippy virus, Mobala and Mopeia (Table 2) [7,13,31,32].…”

Section: Virology Of Lassa Fever Virusmentioning

confidence: 99%

See 1 more Smart Citation

Review of Lassa fever, an emerging old world haemorrhagic viral disease in sub-Saharan Africa

Azeez-Akande¹

2016

Af J Clin Exp Micro

View full text Add to dashboard Cite

Lassa fever is an acute immunosuppressive illness of increasing public health concern causing severe morbidity and significant mortality (Case fatality rate (CFR) ≥ 50%) especially in epidemic cases. Although Lassa fever has emerged (following its first detection (1969) in Lassa town, Nigeria) as one of the most prevalent and debilitating viral haemorrhagic fevers endemic in West Africa region (Nigeria inclusive), yet, the control/prevention of the regular outbreak of the disease has become an herculean task in the areas affected; there is inadequate healthcare facility (including Laboratory/diagnostic and care centres), poor socioeconomic environment, lack of awareness among the populace and presence of favourable ecologic niche for the survival and propagation of the natural host and reservoir mouse (Mastomys natalensis) of Lassa virus . Lassa fever is mainly transmitted by contact with excretions and secretions of infected rats via foods and water as well as exposure to other contaminated items. Lassa virus is a member of an Old World Arenariruses, of family Arenaviridae. It is an enveloped, single-stranded (SS) bisegmented RNA virus with ability to replicate very rapidly. It consists of 4 lineages; 3 members are identified as ancenstral strains found in Nigeria, while the fourth is domiciled in other West Africa Countries. Lassa virus infects almost every tissue in human body resulting in multisystemic dysfunction. The incubation period is generally between 6 to 21 days resulting in 3 stages of clinical manifestation viz: Acute phase characterized by flu-like, non-specific illness; haemorrhagic phase accompanied with gastrointestinal symptoms and cardiovascular/neurologic complications. Currently, there is no clinically certified Lassa fever vaccine thus complicating deterrent or preventive measures. Hence, there is need for intensification of educational programs for the populace on the useful control measures against Lassa fever. The stakeholders need to prioritize intervention and support program and also speed up the processes leading to the production of effective vaccine to limit the menace of Lassa fever outbreak and associated morbidity, fatality and high socio-economic cost.

show abstract

A case of Lassa fever: clinical and virological findings.

Cited by 47 publications

References 5 publications

Structural and Cell-associated Proteins of Lassa Virus

Structural and Cell-associated Proteins of Lassa Virus

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Review of Lassa fever, an emerging old world haemorrhagic viral disease in sub-Saharan Africa

Contact Info

Product

Resources

About